Skip to content
  • Print

Mamoun M. Alhamadsheh, PhD

Associate Professor

Contact

Phone: 209.946.3164
Email: malhamadsheh@pacific.edu
Website: Research Lab

Education

BS in Pharmacy, Jordan University of Science and Technology, 1999

PhD in Medicinal Chemistry, University of Toledo, 2004

PostDoc, Portland State University, 2004-2007

PostDoc, Stanford University, 2008-2011

At Pacific Since: 2011

Mamoun M. Alhamadsheh, PhD earned his bachelor of pharmacy from Jordan University of Science and Technology in Irbid, Jordan. He earned his doctor of philosophy from University of Toledo in Ohio. He also completed post-doctoral training at Portland State University and Stanford University. Dr. Alhamadsheh joined the Pacific family in 2011. He loves interacting with students at Pacific and sharing his enthusiasm for his research activities.

Since 2011 he has been involved with the Rho Chi Honor Society. Dr. Alhamadsheh has been a member of the American Association of Pharmaceutical Scientists since 2014. In addition, he has been an active member of the American Association of Colleges of Pharmacy (AACP) since 2011. Dr. Alhamadsheh was awarded the 2011-2012 AACP New Investigator Award for his research titled Harnessing Transthyretin to Inhibit Extracellular Receptor-Ligand Interactions. The goal of his research is to find a more stable, less toxic and inexpensive alternative for targeting antibodies.

In 2011 Dr. Alhamadsheh had his article “Potent Kinetic Stabilizers That Prevent Transthyretin-Mediated Cardiomyocyte Proteotoxicity“ published and featured on the cover of Science Translational Medicine magazine. It was also mentioned in the Chemical & Engineering News published by the American Chemical Society and The Alzheimer’s Research Forum.

 

Teaching Philosophy: "My ultimate goal as a professor is to provide students with the foundational knowledge to solve real-life problems. In the classroom, I always encourage students to ask questions and engage in discussions in order to become critical thinkers. I try my best to inspire students and show them that what they learn in class would allow them to make a difference in providing the best therapy for patients. Most importantly, I make sure that clinical relevance is introduced to the material taught in class. This has made the course not only intellectually stimulating but also interesting to the students."

Courses:

PHRM 135 - Pharmacology & Medicinal Chemistry I
PHRM 113 - Molecular & Cellular Biochemistry
PMED143 - TA for Molecular & Cellular Biochemistry
PCSP 208 - Pharmaceutical Analysis
PMED 193A - PharmD Independent Study
PCSP 397 - Graduate Research
PCSP 299 - Graduate Thesis

 

Research Summary: "Our lab employs an interdisciplinary chemical biology approach to study protein-protein interactions (PPIs). We are interested in developing small molecules that can be used to probe or inhibit PPIs. These small molecules would be used to understand the structure and function of multi-protein complexes as well as to develop new leads for drug discovery. Due to the urgent need for new drugs, we are particularly interested in developing chemical tools and therapeutic agents for protein aggregation (a type of PPIs) diseases such as Alzheimer's disease and Transthyretin Amyloidosis.

Our group is also interested in developing novel approaches for drug targeting and delivery. These approaches are aimed at decreasing cost and increasing clinical success rate of therapeutic agents."

Research Interests:

  • Protein-Protein Interactions
  • Amyloid Beta Aggregation in Alzheimer's Disease
  • Transthyretin Amyloidosis

 

Mamoun Alhamadsheh, BPharm, PhD, had his paper "A biomimetic approach for enhancing the in vivo half-life of peptides" published in the Nature Chemical Biology Journal. Co-authors are Sravan C. Penchala '16, Mark R. Miller '17, Arindom Pal '19, Jin Dong '16, Nikhil R. Madadi '15, Jinghang Xie '14, Hyun Joo (Chemistry), Jerry Tsai (Chemistry), Patrick Batoon '16 (Chemistry), Vyacheslav Samoshin (Chemistry), Andreas Franz (Chemistry), Trever Cox '14, Jesse Miles '15, William K. Chan, PharmD, PhD, Professor of Pharmaceutics and Medicinal Chemistry and Miki S. Park, PhD, Associate Professor of Pharmaceutics and Medicinal Chemistry. Click here to read more.

Penchala SC, Connelly S, Wang Y, Park MS, Zhao L, Baranczak A, Rappley I, Vogel H, Liedtke M, Witteles RM, Powers ET, Reixach N, Chan WK, Wilson IA, Kelly JW, Graef IA, Alhamadsheh MM. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Proc. Natl. Acad. Sci. USA. 2013;110:9992-9997.

Mamoun Alhamadsheh had his article "Potent Kinetic Stabilizers That Prevent Transthyretin-Mediated Cardiomyocyte Proteotoxicity" published and featured on the cover of Science Translational Medicine magazine. It was also mentioned in Chemical & Engineering News, published by the American Chemical Society, and The Alzheimer Research Forum.